Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY – Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 12,900 shares, an increase of 545.0% from the July 31st total of 2,000 shares. Based on an average daily volume of 106,800 shares, the short-interest ratio is presently 0.1 days.
Chugai Pharmaceutical Stock Performance
OTCMKTS CHGCY opened at $25.37 on Wednesday. Chugai Pharmaceutical has a one year low of $13.85 and a one year high of $25.99. The firm has a market cap of $83.47 billion, a PE ratio of 37.31 and a beta of 0.87. The firm’s fifty day moving average is $19.99 and its two-hundred day moving average is $18.45.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last released its earnings results on Thursday, July 25th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. The company had revenue of $2.03 billion during the quarter. Research analysts predict that Chugai Pharmaceutical will post 0.78 earnings per share for the current year.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Read More
- Five stocks we like better than Chugai Pharmaceutical
- 5 discounted opportunities for dividend growth investors
- Sleeper AI-Winner Ambarella Will More Than Triple in Price
- What is Insider Trading? What You Can Learn from Insider Trading
- Gold vs. Silver: Which Is the Better Investment in the New Cycle?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Best Growth Stocks to Own for the Next 10 Years
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.